Page 1187 - Clinical Immunology_ Principles and Practice ( PDFDrive )

1152 ParT TEN Prevention and Therapy of Immunological Diseases

Please check your eBook at https://expertconsult.inkling.com/ immunoglobulins for primary immunodeficiency. J Allergy Clin
for self-assessment questions. See inside cover for registration Immunol 2012;130:951–7.
details. 19. Wasserman RL. Progress in gammaglobulin therapy for
immunodeficiency: from subcutaneous to intravenous infusions and back
again. J Clin Immunol 2012;32(6):1153–64.
REFERENCES 20. Bonilla FA. Pharmacokinetics of immunoglobulin administered via
intravenous or subcutaneous routes. Immunol Allergy Clin North Am
1. Orange JS, Hossny EM, Weiler CR, et al. Use of intravenous 2008;28(4):803–19, ix.
immunoglobulin in human disease: a review of evidence by members of 21. Stiehm ER. Adverse effects of human immunoglobulin therapy. Transfus
the Primary Immunodeficiency Committee of the American Academy of Med Rev 2013;27:171–8.
Allergy, Asthma and Immunology. J Allergy Clin Immunol 22. Daniel GW, Menis M, Sridhar G, et al. Immune globulins and thrombotic
2006;117:S525–53. adverse events as recorded in a large administrative database in 2008
2. Perez E, Bonilla T, Chinen J, et al. Update on the use of Immune Globulin through 2010. Transfusion 2012;52:2113–21.
(IG) in human disease: a review of evidence by members of the primary 23. Farrugia A, Quinti I. Manufacture of immunoglobulin products for
immunodeficiency committee of the American Academy of Allergy, patients with primary antibody deficiencies- the effect of processing
Asthma and Immunology. J Allergy Clin Immunol 2017;139(3):S1–46. conditions on product safety and efficacy. Front Immunol 2014;5:
3. Quartier P, Debre M, DeBlie J, et al. Early and prolonged 1–8.
intravenous immunoglobulin replacement therapy in childhood 24. Horn J, Thon V, Bartonkova D, et al. Anti-IgA antibodies in common
agammaglobulinemia: a retrospective survey of 31 patients. J Pediatrics variable immunodeficiency (CVID): diagnostic workup and therapeutic
1999;134:589–96. strategy. Clin immunol 2007;122(2):156–62.
4. Orange JS, Grossman WJ, Navickis RJ, et al. Impact of trough IgG on 25. Rachid R, Bonilla FA. The role of anti-IgA antibodies in causing adverse
pneumonia incidence in primary immunodeficiency: a meta-analysis of reactions to gamma globulin infusion in immunodeficient patients: a
clinical studies. Clin immunol 2010;137(1):21–30. comprehensive review of the literature. J Allergy Clin Immunol
5. Bonagura VR, Marchlewski R, Cox A, et al. Biologic IgG level in primary 2012;129(3):628–34.
immunodeficiency disease: the IgG level that protects against recurrent 26. Dalakas M. Mechanistics effects of IVIG in neuroinflammatory diseases:
infection. J Allergy Clin Immunol 2008;122(1):210–12. conclusions based on clinicopathologic correlations. J Clin Immunol
6. Lucas M, Lee M, Lortan J, et al. Infection outcomes in patients with 2014;34(Suppl1):S120–6.
common variable immunodeficiency disorders: relationship to 27. Buchwald B, Ahangari R, Weishaupt A, et al. Intravenous
immunoglobulin therapy over 22 years. J Allergy Clin Immunol immunoglobulins neutralize blocking antibodies in Guillain-Barre
2010;125(6):1354–60 e4. syndrome. Ann Neurol 2002;51:673–80.
7. Jiang F, Torgerson TR, Ayars AG. Health-related quality of life in patients 28. Li N, Zhao M, Hilario-Vargas J, et al. Complete FcRn dependence for
with primary immunodeficiency disease. Allergy Asthma Clin Immunol intravenous Ig therapy in autoimmune skin blistering diseases. J Clin
2015;11:27–38. Invest 2005;115:3440–50.
8. Routes J, Costa-Carvalho B, Grimbacher B, et al. Health-related quality of 29. Hansen RJ, Balthasar JP. Effects of intravenous immunoglobulin on
life and health resource utilization in patients with primary platelet count and antiplatelet antibody disposition in a rat model of
immunodeficiency disease prior to and following 12 months of immune thrombocytopenia. Blood 2002;100:2087–93.
immunoglobulin G treatment. J Clin Immunol 2016;36(5):450–61. 30. Hansen RJ, Balthasar JP. Mechanisms of IVIG action in immune
9. Jolles S, Orange JS, Gardulf A, et al. Current treatment options with thrombocytopenic purpura. Clin Lab 2004;50:133–40.
immunoglobulin G for the individualization of care in patients with 31. Samuelsson A, Towers TL, Ravetch JV. Anti-inflammatory activity of IVIG
primary immunodeficiency disease. Clin Exp Immunol 2015;179: mediated through the inhibitory Fc receptor. Science 2001;291:484–6.
146–60. 32. Kaneko Y, Nimmerjahn F, Ravetch JV. Anti-inflammatory activity of
10. Berger M, Rojavin M, Kiessling P, et al. Pharmacokinetics of immunoglobulin G resulting from Fc sialylation. Science 2006;313:670–3.
subcutaneous immunoglobulin and their use in dosing of replacement 33. Anthony RM, Nimmerjahn F, Ashline D, et al. Recapitulation of IVIG
therapy in patients with primary immunodeficiencies. Clin immunol anti-inflammatory activity with a recombinant IgG Fc. Science
2011;139(2):133–41. PubMed PMID: 21353644. 2008;320(373-376).
11. Berger M. Subcutaneous administration of IgG. Immunol Allergy Clin 34. Anthony RM, Wermeling F, Karlsson M, et al. Identification of a receptor
North Am 2008;28(4):779–802, viii. required for the anti-inflammatory activity of IVIG. Proc Natl Acad Sci
12. Lawo J-P, Hubsch A, Rojavin M. Quantification of the wear-off effect USA 2008;105:19571–8.
towards the end of the IVIG infusion interval:Pooled data analysis. 35. Anthony RM, Kobayashi T, Wermeling F, et al. Intravenous
J Allergy Clin Immunol 2014;133(2):AB179. gammaglobulin suppresses inflammation through a novel T(H)2 pathway.
13. Berger M, Jolles S, Orange JS, et al. Bioavailability of IgG administered by Nature 2011;475(7354):110–13.
the subcutaneous route. J Clin Immunol 2013;33(5):984–90. 36. Tackenberg B, Jelcic I, Baerenwaldt A, et al. Impaired inhibitory Fcgamma
14. Ducruet T, Levasseur M-C, Roches A, et al. Pharmacoeconomic receptor IIB expression on B cells in chronic inflammatory demyelinating
advantages of subcutaneous versus intravenous immunoglobulin polyneuropathy. Proc Natl Acad Sci USA 2009;106(12):4788–92.
treatment in a Canadian pediatric center. J Allergy Clin Immunol 37. Campbell IK, Miescher S, Branch DR, et al. Therapeutic effect of IVIG on
2013;131(2):585–7. inflammatory arthritis in mice is dependent on the Fc portion and
15. Fasth A, Nystrom J. Quality of life and health-care resource utilization independent of sialylation or basophils. J Immunol 2014;192(11):
among children with primary immunodeficiency receiving home 5031–8.
treatment with subcutaneous human immunoglobulin. J Clin Immunol 38. Bayry J, Bansal K, Kazatchkine M, et al. DC-SIGN and a2,6-sialylated IgG
2008;28(4):370–8. Fc interaction is dispensable for the anti-inflammatory activity of IVIG.
16. Misbah S, Sturzenegger MH, Borte M, et al. Subcutaneous Proc Natl Acad Sci USA 2009;106:E24.
immunoglobulin: opportunities and outlook. Clin Exp Immunol 39. Yu X, Vasiljevic S, Mitchell DA, et al. Dissecting the molecular mechanism
2009;158(Suppl. 1):51–9. of IVIg therapy: the interaction between serum IgG and DC-SIGN is
17. Ponsford M, Carne E, Kingdon C, et al. Facilitated subcutaneous independent of antibody glycoform or Fc domain. J Mol Biol
immunoglobulin (fSCIg) therapy- practical considerations. Clin Exp 2013;425(8):1253–8.
Immunol 2015;182:302–13. 40. Burns J, Franco A. Ihe immunomodulatory effects off intravenous
18. Wasserman RL, Melamed I, Stein MR, et al. Recombinant human immunoglobulin therapy in Kawasaki disease. Expert Rev Clin Immunol
hyaluronidase-facilitated subcutaneous infusion of human 2015;11(I7):819–25.